Blue Earth Diagnostics, a Bracco company, is highlighting findings from the phase III Spotlight study regarding its Posluma (flotufolastat F-18) injection for prostate cancer. The results were published recently in Advances in Radiation Oncology.
The study assessed the use of FDA-approved Posluma in patients with recurrent prostate cancer, specifically its efficacy for African American men.
The study found that 93% of the African American cohort had a positive Posluma scan, consistent with the 87% detection rate for all other patients in the study. African American men accounted for 17% of the total study population.
Posluma is approved in the U.S. for PET imaging of prostate specific membrane antigen-positive lesions in men with prostate cancer. These patients also have suspected metastases and are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen levels.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
